LRP-1-targeted Peptide-drug Conjugate GRN1005

A peptide-drug conjugate containing the taxane paclitaxel covalently linked to the proprietary 19 amino acid peptide angiopep-2, in a 3:1 ratio, with potential antineoplastic activity. Upon administration, LRP-1-targeted peptide-drug conjugate GRN1005, via angiopep-2 moiety, binds to LRP-1 (low density lipoprotein receptor-related protein 1), which is highly expressed in blood brain barrier (BBB) and glioma cells. This binding allows the transcytosis of the agent across the BBB and the delivery of the cytotoxic agent paclitaxel. Compared to paclitaxel alone, GRN1005 is able to increase the concentration of paclitaxel in the brain and is also able to specifically deliver paclitaxel to LRP-1-overexpressing tumor cells, both in the brain and in the periphery. (NCI Thesaurus)

YOU MAY ALSO LIKE

LRIG3 wt Allele

Human LRIG3 wild-type allele is located in the vicinity of 12q14.1 and is approximately 48 kb in length. This allele, which encodes…

LRIG3 Gene

This gene may be involved in signaling.

LRIG1 wt Allele

Human LRIG1 wild-type allele is located in the vicinity of 3p14 and is approximately 122 kb in length. This allele, which encodes…

LRIG1 Gene

This gene is involved in the regulation of signal transduction.

LPP/MLL Fusion Protein

A fusion protein encoded by the LPP/MLL fusion gene. This protein is comprised of the N-terminal half of the lipoma-preferred partner protein,…

LPP/MLL Fusion Gene

A fusion gene that results from a chromosomal translocation t(3;11)(q28;q23) which fuses exon 8 of the LPP gene to exon 9 of…